Other Events ·
Tiziana doses last patient in Phase 2 trial of intranasal foralumab for mild Alzheimer's disease
TLSATiziana Life Sciences Ltd
Tiziana Life Sciences completed enrollment and initiated dosing for all participants in its Phase 2 randomized, placebo-controlled clinical trial evaluating intranasal foralumab in patients with early or mild Alzheimer’s disease. The study assesses the safety, tolerability, and potential efficacy of the therapy as a monotherapy and in combination with FDA-approved anti-amyloid treatments lecanemab or donanemab. Topline data from the trial are anticipated to be announced in Q1 2027. Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies for immunomodulation.